Phase II randomized 6‑way PK study of CHF 1535 NEXThaler with charcoal

Phase 2, randomised, open-label trial of beclometasone dipropionate + formoterol in asthma and chronic obstructive pulmonary disease (COPD) (6 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoints: Lung bioavailability of B17MP and formoterol (AUC0–t) with activated charcoal and Lung bioavailability and systemic exposure of beclometasone dipropionate with and without activated charcoal. Started Sep 2012; status: completed.